placeholder image
K. A. B. Goddard All authors
About
Publications While At HealthPartners
selected publications
Journal Article
  • Attitudes toward COVID-19 vaccines among pregnant and recently pregnant individuals
    JAMA network open. 2024
  • Clinical epidemiology and risk factors for critical outcomes among vaccinated and unvaccinated adults hospitalized with COVID-19-VISION Network, 10 states, June 2021-March 2023
    Clinical Infectious Diseases. 2024
  • Influenza vaccine effectiveness against influenza A-associated emergency department, urgent care, and hospitalization encounters among US adults, 2022-2023
    Journal of Infectious Diseases. 2024
  • Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis
    Lancet (London, England). 2024
  • Vaccine effectiveness against pediatric influenza-A-associated urgent care, emergency department, and hospital encounters during the 2022-2023 season: VISION Network
    Clinical Infectious Diseases. 2024
  • Effectiveness of BNT162b2 COVID-19 vaccination in children and adolescents
    Pediatrics. 2023
  • Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: an observational study of real-world data across 10 US states from August-December 2021
    Vaccine. 2023
  • Estimates of bivalent mRNA vaccine durability in preventing COVID-19-associated hospitalization and critical illness among adults with and without immunocompromising conditions - VISION Network, September 2022-April 2023
    American Journal of Transplantation. 2023
  • Estimation of COVID-19 mRNA vaccine effectiveness and COVID-19 illness and severity by vaccination status during Omicron BA.4 and BA.5 sublineage periods
    JAMA network open. 2023
  • Influenza vaccination coverage among persons ages six months and older in the Vaccine Safety Datalink in the 2017-18 through 2022-23 influenza seasons
    Vaccine. 2023
  • Protection of two and three mRNA vaccine doses against severe outcomes among adults hospitalized with COVID-19--VISION Network, August 2021 to March 2022
    Journal of Infectious Diseases. 2023
  • Racial and ethnic disparities in influenza vaccination coverage among pregnant women in the United States: the contribution of vaccine-related attitudes
    Preventive Medicine. 2023
  • Safety of simultaneous vaccination with COVID-19 vaccines in the Vaccine Safety Datalink
    Vaccine. 2023
  • Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines
    Vaccine. 2023
  • Vaccine effectiveness against influenza-associated urgent care, emergency department, and hospital encounters during the 2021-2022 season, VISION Network
    Journal of Infectious Diseases. 2023
  • Developing an algorithm across integrated healthcare systems to identify a history of cancer using electronic medical records
    Journal of the American Medical Informatics Association. 2022
  • Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19-associated emergency department or urgent care encounters and hospitalizations among immunocompetent adults - VISION Network, nine states, September-November 2022
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of 2, 3, and 4 COVID-19 mRNA vaccine doses among immunocompetent adults during periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 sublineages predominated - VISION Network, 10 states, December 2021-June 2022
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19-associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5-17 years - VISION Network, 10 states, April 2021-January 2022
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of COVID-19 mRNA vaccines against COVID-19-associated hospitalizations among immunocompromised adults during SARS-CoV-2 Omicron predominance - VISION Network, 10 states, December 2021-August 2022
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during oeriods of Delta and Omicron variant predominance - VISION Network, 10 states, August 2021-January 2022
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of homologous and heterologous COVID-19 booster doses following 1 Ad.26.COV2.S (Janssen (Johnson & Johnson)) vaccine dose against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults - VISION Network, 10 states, December 2021-March 2022
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults-nine states, January-September 2021
    American Journal of Transplantation. 2022
  • Estimation of COVID-19 mRNA vaccine effectiveness against medically attended COVID-19 in pregnancy during periods of Delta and Omicron variant predominance in the United States
    JAMA network open. 2022
  • Incidence of Guillain-Barré syndrome after COVID-19 vaccination in the Vaccine Safety Datalink
    JAMA network open. 2022
  • Monitoring vaccine safety using the Vaccine Safety Datalink: assessing capacity to integrate data from Immunization Information systems
    Vaccine. 2022
  • Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination
    Vaccine. 2022
  • Safety of COVID-19 vaccination in United States children ages 5 to 11 years
    Pediatrics. 2022
  • Safety of live-attenuated vaccines in children exposed to biologic response modifiers in utero
    Pediatrics. 2022
  • Travelers and travel vaccines at six health care systems in the Vaccine Safety Datalink
    Vaccine. 2022
  • Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance - VISION Network, 10 states, August 2021-January 2022
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study
    BMJ (Clinical research ed.). 2022
  • COVID-19 vaccination coverage among insured persons aged ≥16 years, by race/ethnicity and other selected characteristics - eight integrated health care organizations, United States, December 14, 2020-May 15, 2021
    MMWR: Morbidity and Mortality Weekly Report. 2021
  • Effectiveness of 2-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults - nine states, January-September 2021
    MMWR: Morbidity and Mortality Weekly Report. 2021
  • Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings
    New England Journal of Medicine. 2021
  • Laboratory-confirmed COVID-19 among adults hospitalized with COVID-19-like illness with infection-induced or mRNA vaccine-induced SARS-CoV-2 immunity - nine states, January-September 2021
    MMWR: Morbidity and Mortality Weekly Report. 2021
  • Surveillance for adverse events after COVID-19 mRNA vaccination
    JAMA. 2021
  • Does KRAS testing in metastatic colorectal cancer impact overall survival? A comparative effectiveness study in a population-based sample
    PloS One. 2014
  • KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings
    Cancer Epidemiology, Biomarkers and Prevention. 2013
  • Oncologists' attitudes toward KRAS testing: a multisite study
    Cancer medicine. 2013
  • Underutilization of Lynch syndrome screening in a multisite study of patients with colorectal cancer
    Genetics in Medicine. 2013
  • Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer
    Journal of the National Cancer Institute. 2012
  • Barriers in identification and referral to genetic counseling for familial cancer risk: the perspective of genetic service providers
    Journal of genetic counseling. 2011
  • Contact
    full name
  • K. A. B. Goddard
  • Quick Info
     
    Collaboration